phase readout
saveNCT03847428: Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
ACTIVE_NOT_RECRUITINGupdated 12m ago
community read0 votes
Sponsor: AstraZeneca. Phase: PHASE3. Conditions: Hepatocellular Carcinoma
view source ↗
comments(0)
5-min edit window · permanent after that